<DOC>
	<DOCNO>NCT01292551</DOCNO>
	<brief_summary>The purpose study determine whether Bosentan effective safe treatment adolescent adult ( 15 year old ) patient , bear one ventricle heart instead two ( single ventricle physiology ) undergone TCPC palliative surgical treatment . The aim TCPC operation use one functioning ventricle pump blood flow body , blood lung receive directly caval vein , thus passive flow , without aid ventricle actively pump blood pulmonary circulation . The resistance pulmonary circulation therefore critical patient . These patient markedly low work capacity bicycle test general public . Furthermore high risk develop complication e.g . loss protein intestine . Bosentan medication lower resistance pulmonary circulation . It routinely use patient pulmonary hypertension . Some study show drug low pulmonary resistance increase exercise capacity significantly patient single ventricle physiology . In study 80 patient receive either placebo Bosentan 14 week . Before treatment , bicycle test along blood sample , stool sample quality life interview perform . Every four week study blood sample , physical exam interview perform ensure safety treatment . The investigator expect find significant increase work capacity 14 week treatment group compare placebo group . Moreover investigator hope find decrease intestinal protein loss improve quality life .</brief_summary>
	<brief_title>Study Placebo Bosentan Treat Patients With Single Ventricle Physiology .</brief_title>
	<detailed_description>In statistical analysis investigator wish analyse interaction primary endpoint predefined subgroup order distinguish responder non-responders treatment . The predefined subgroup : NT-proBNP &gt; 100 ( yes/no ) Ventricular anatomy ( RV/LV ) CT-proEndothelin-1 . In latter , investigator wish predefine specific value , due limit experience analysis . We wish use data study find cut-off value , able predict positive response treatment .</detailed_description>
	<mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Tricuspid Atresia</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>TCPC operate Age &gt; 15 year old Clinical stability &gt; 3 month , evaluate investigator clinical record For woman : Negative shCG use contraception Severe heart failure ( NYHAclass IV ) Oxygen saturation &lt; 85 % rest Preexisting liver condition ( transaminases 2x &gt; reference ) Renal failure ( creatinin &gt; 150 mmol/l ) Obstruction TCPC circulation History work induce severe arrhythmia Systolic blood pressure 80 % reference ( BT &lt; 88 mmHg ) Use follow drug : Fluconazol , Ketoconazole , CiclosporinA , Lopinavir , Ritonavir , Rifampicin , Carbamazepin Phenytoin Significant extracardiac condition e.g . neurological impairment</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>single ventricle physiology</keyword>
	<keyword>Fontan procedure</keyword>
</DOC>